Bellevue Life Sciences Acquisition CORP Form 4 insider transactions

Bellevue Global Life Science Investors LLC reports acquiring 43,000 shares of OSR Holdings, Inc. common stock following the conversion of private placement rights related to a business combination.

Kuk Hyoun Hwang, President and CEO of OSR Holdings, reports the acquisition of shares through conversions and a business combination, significantly increasing his indirect beneficial ownership.

Bellevue Life Sciences Acquisition Corp. (BLAC) finalizes its business combination with OSR Holdings Co., Ltd., changing its name to OSR Holdings, Inc. and preparing to trade on the Nasdaq.

Bellevue Life Sciences Acquisition Corp. has amended its business combination agreement with OSR Holdings and its PIPE subscription agreement with Toonon Partners, modifying redemption features and put/call rights.

Bellevue Life Sciences Acquisition Corp. has extended a $300,000 loan to OSR Holdings Co., Ltd. to support working capital and other expenses.

Bellevue Life Sciences Acquisition Corp. has entered into a subscription agreement with Toonon Partners Co., Ltd. for a $20 million PIPE investment to support its business combination with OSR Holdings Co., Ltd.

Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd. have amended their business combination agreement, adjusting the aggregate consideration and removing references to a previous acquisition target.

Bellevue Life Sciences Acquisition Corp. reminds stockholders to vote in favor of the proposal to extend the date by which it has to consummate a business combination at the upcoming Special Meeting on May 14, 2024.

Bellevue Life Sciences Acquisition Corp. adjourned its special stockholder meeting on May 10, 2024, and will reconvene on May 14, 2024, to continue soliciting proxies for the matters described in the definitive proxy statement.